文献速递中医内科中药与中成药合理使用

黄芪-莪术药对通过EGFR/AKT/mTOR通路抑制肝癌并诱导铁死亡

Astragali radix - Curcumae rhizoma herb pair suppresses hepatocellular carcinoma through EGFR/AKT/mTOR pathway and induces lipid peroxidation-related ferroptosis via HIF-1α/HO-1/GPX4 axis.
PubMed 文献 · J Ethnopharmacol · 2025-04-30

该研究探讨黄芪-莪术药对(ACHP)抗肝细胞癌(HCC)的作用与机制。体内外实验表明,ACHP较单味药更显著抑制肿瘤增殖且安全性良好,其机制涉及抑制EGFR/AKT/mTOR通路及通过HIF-1α/HO-1/GPX4轴诱导脂质过氧化相关铁死亡。

要点

  • ACHP较黄芪、莪术单用更显著抑制HCC肿瘤增殖,并显示良好安全性。
  • ACHP抗HCC机制包括抑制EGFR/AKT/mTOR致癌信号通路。
  • ACHP通过HIF-1α/HO-1/GPX4轴诱导脂质过氧化相关铁死亡。

核心结论

  • ACHP通过抑制EGFR/AKT/mTOR通路并经由HIF-1α/HO-1/GPX4轴诱导脂质过氧化相关铁死亡,发挥抗HCC作用。

研究设计与样本

  • 研究采用体内HCC模型评估ACHP疗效与安全性,并以UPLC-Q-TOF-MS/MS鉴定血清代谢物。
  • 通过转录组学、网络药理学和分子对接筛选关键靶点与潜在机制。
  • 体外以含ACHP血清处理HCC细胞,采用MTT、克隆形成实验和特异性检测试剂盒评估铁死亡。
  • 体内采用免疫组化检测铁死亡相关蛋白及通路表达。

主要发现

  • ACHP较两味药单用显著抑制肿瘤增殖,并显示良好安全性。
  • 正负离子模式下共鉴定出75种血清代谢物。
  • 转录组学揭示铁死亡在ACHP抗HCC过程中起关键作用。
  • 网络药理学与分子对接提示ACHP抗HCC作用可能与EGFR/AKT/mTOR通路及HIF-1α/HO-1/GPX4轴相关。
  • 体内外实验证实ACHP抑制HepG2细胞增殖及HCC小鼠肿瘤生长。

临床怎么用

  • ACHP可作为靶向致癌信号网络的铁死亡诱导剂,为HCC治疗提供潜在中药药对选择。
  • 临床可基于EGFR/AKT/mTOR通路及HIF-1α/HO-1/GPX4轴相关标志物探索ACHP抗HCC疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: The Astragali Radix - Curcumae Rhizoma herb pair (ACHP) originated from the famous traditional Chinese medicine text "YiXueZhongZhongCanXiLu", in which the two herbs were paired to form Chinese herbal compounds commonly used clinically for digestive system tumors, such as hepatocellular carcinoma (HCC). Although ACHP has been inherited for thousands of years in China, its mechanism against HCC remains unclear. AIM OF THE STUDY: The study aims to evaluate the effect and explore the mechanism of ACHP against HCC. METHODS: The efficacy and safety of ACHP against HCC in vivo were evaluated by tumor volume, organ index, H&E staining, hepatic and renal factors. The serum metabolites of ACHP were identified by UPLC-Q-TOF-MS/MS. The key targets and potential mechanisms of ACHP against HCC were screened by transcriptomics, network pharmacology and molecular docking. The effect and induction of ferroptosis of ACHP-containing serum on HCC in vitro was evaluated by MTT, colony formation assay and specific detection kits. The expression of ferroptosis-related proteins and pathways in vivo was detected by immunohistochemistry. RESULTS: ACHP significantly inhibited tumor proliferation compared to the two herbs used separately, and showed a favorable safety profile. A total of 75 serum metabolites were identified in both positive and negative ion modes. Transcriptomics results revealed that ferroptosis played a key role in the anti-HCC process of ACHP. Network pharmacology and molecular docking results suggested that the anti-HCC effect of ACHP may be related to EGFR/AKT/mTOR pathway and HIF-1α/HO-1/GPX4 axis. In vitro and in vivo experiments further demonstrated that ACHP suppressed oncogenic signaling via the EGFR/AKT/mTOR pathway while inducing lipid peroxidation-related ferroptosis through HIF-1α/HO-1/GPX4 axis, thereby inhibiting HepG2 cells proliferation and HCC mice tumor growth. CONCLUSION: ACHP exerts its effects by suppressing oncogenic signaling through the EGFR/AKT/mTOR pathway and inducing lipid peroxidation-related ferroptosis in HCC via the HIF-1α/HO-1/GPX4 axis. This systematic investigation establishes a coherent pharmacological chain from compound identification to mechanism verification, highlighting ACHP's therapeutic potential as a ferroptosis inducer targeting oncogenic signaling networks in HCC.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Wang C, Shi CH, Bai HY, et al. Astragali radix - Curcumae rhizoma herb pair suppresses hepatocellular carcinoma through EGFR/AKT/mTOR pathway and induces lipid peroxidation-related ferroptosis via HIF-1α/HO-1/GPX4 axis. J Ethnopharmacol. 2025. PMID: 40316156. doi:10.1016/j.jep.2025.119912

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。